<DOC>
	<DOCNO>NCT02593409</DOCNO>
	<brief_summary>Can HIV-specific immunity develop HIV uninfected human expose HIV whilst receive antiretroviral pre-exposure prophylaxis ( PrEP ) ? Investigators investigate possibility commercial sex worker Kampala receive Truvada PrEP one year .</brief_summary>
	<brief_title>HIV PrEP Priming Immune Effectors</brief_title>
	<detailed_description>Design This single centre open label longitudinal observational trial . Women attend `` Good Health Women '' clinic inform objective trial volunteer able provide inform consent high risk exposure HIV-1 determine sexual history questionnaire screen Rapid antibody test . Seronegatives check eligibility clinical examination laboratory test . The endpoint enrolment 220 uninfected high risk participant . Baseline blood sample obtain participant month 0 . A monthly diary card provide self document sexual exposure , alcohol use pill take . Participants receive provision PrEP ( tenofovir disoproxil fumarate ( TDF ) emtricitabine ( FTC ) sufficient one month , instruct daily prophylaxis record adherence diary card . Participants ask return month treatment re-provisioning new card . The content diary card discuss short interview month . At month 6 12 blood sample collect evaluate immune response HIV-1 . Additional test do monitor HIV-1 status , pregnancy sexually transmit infection ( STIs ) . After month 12 PrEP discontinue ( unless participant opt continue PrEP end follow ) participant provide blood sample month 18 . Baseline follow-up peripheral blood mononuclear cell ( PBMC ) sample compare T cell response HIV interferon-γ ( IFN-γ ) enzyme-linked immunospot ( ELISPOT ) . In case positive immune response , plasma collect time point nucleic acid test ( NAT ) test verify absence HIV infection . HIV infect participant evaluate cluster differentiation 4 ( CD4 ) T cell viral load refer Care Program ( PEPFAR ) . At month 6 , 12 18 in-depth interview conduct randomly select sample 44 woman ( 20 percent ) discus facilitator barrier adherence . The diary answer tabulate look pattern trend . A framework approach analysis use analysis qualitative data interview .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>age ≥18 screen intend move away clinic 's catchment area next 2 year HIV1 antibody negative report commercial sex work contact information provide write informed consent HIV infection screen participation previous concurrent HIV vaccine trial lactate , pregnant planning pregnancy renal function impairment ( serum creatinine &gt; 1.5 mg/dl ) , Fanconi syndrome abnormal liver function test ( AST/ALT &gt; 43 U/L ) , liver disease , viral hepatitis , hepatitis B virus ( HBV ) infection serum phosphorus &lt; 2.2mg/dl , osteoporosis know sensitivity component Truvada® formulation immunosuppressive treatment , systemic corticosteroid assumption medication interact Truvada® high likelihood poor adherence PREP clinic attendance condition opinion attend physician could endanger health participant render unsuitable participate trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>pre-exposure prophylaxis ( PrEP )</keyword>
	<keyword>immune response</keyword>
</DOC>